Download MendeleyDiscovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
Ye, G., Pan, R., Bu, F., Zheng, J., Mendoza, A., Wen, W., Du, L., Spiller, B., Wadzinski, B.E., Liu, B., Perlman, S., Li, F.(2023) J Virol 97: e0144823-e0144823
- PubMed: 37855638
- DOI: https://doi.org/10.1128/jvi.01448-23
- Primary Citation of Related Structures:
8G72, 8G73, 8G74, 8G75 - PubMed Abstract:
The COVID-19 pandemic exposed limitations of conventional antibodies as therapeutics, including high cost, limited potency, ineffectiveness against new viral variants, and primary reliance on injection-only delivery. Nanobodies are single-domain antibodies with therapeutic potentials. We discovered three anti-SARS-CoV-2 nanobodies, named Nanosota-2, -3, and -4, from an immunized alpaca. Nanosota-2 is super potent against prototypic SARS-CoV-2, Nanosota-3 is highly potent against the omicron variant, and Nanosota-4 is effective against both SARS-CoV-1 and SARS-CoV-2. In addition to their super potency and combined broad antiviral spectrum, these nanobodies are cost-effective, can be easily adapted to new viral variants through phage display, and can potentially be administered as inhalers. The Nanosota series are powerful therapeutic candidates to combat circulating SARS-CoV-2 and prepare for possible future coronavirus pandemics.
Organizational Affiliation:
Department of Pharmacology, University of Minnesota Medical School , Minneapolis, Minnesota, USA.
